论文部分内容阅读
目的:分析肾透明细胞癌的CT分期与增殖细胞核抗原(PCNA)和bcl 2表达的关系。方法:对51 例经手术病理证实的肾透明细胞癌,采用免疫组化LDP法检测肿瘤标本中PCNA和bcl 2的表达,并对肿瘤进行病理分级,分析其与术前CT分期的关系。结果:PCNA表达与CT分期及病理各分级间具有相关性(P<0.05),在CT分期中Ⅰ期与Ⅲ期、Ⅰ期与Ⅳ期、Ⅱ与Ⅲ期、Ⅱ与Ⅳ期、Ⅰ+Ⅱ与Ⅲ+Ⅳ期的PCNA表达差异有显著性意义(P<0.05),而bcl 2 表达与肿瘤病理分级及CT分期均无明显相关(P>0.05)。结论:PCNA的表达与肾透明细胞癌的CT分期、病理分级具有相关性,能较为客观、准确的反映肾透明细胞癌的恶性程度,对选择治疗方法有重要的参考价值。
Objective: To analyze the relationship between CT staging and the expression of proliferating cell nuclear antigen (PCNA) and bcl-2 in clear cell renal cell carcinoma. Methods: 51 cases of renal clear cell carcinoma confirmed by surgery and pathology were examined by immunohistochemical LDP method. The expression of PCNA and bcl2 were detected by immunohistochemistry and the relationship between the expression of PCNA and bcl2 was analyzed. Results: There was a significant correlation between the expression of PCNA and CT staging and histological grade (P <0.05). There was no significant difference in CT staging between stage Ⅰ and Ⅲ, stage Ⅰ and Ⅳ, stage Ⅱ and Ⅲ, stage Ⅱ and Ⅳ, stage Ⅰ + Ⅱ (P <0.05). There was no significant correlation between the expression of bcl-2 and tumor grade and CT staging (P> 0.05). Conclusion: The expression of PCNA is correlated with CT staging and pathological grading of clear cell renal cell carcinoma, which can objectively and accurately reflect the malignant degree of renal clear cell carcinoma and has important reference value for the selection of treatment methods.